<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01712763</url>
  </required_header>
  <id_info>
    <org_study_id>C06/2012</org_study_id>
    <nct_id>NCT01712763</nct_id>
  </id_info>
  <brief_title>Degarelix in the Treatment of Endometriosis Recurrence</brief_title>
  <official_title>Treatment With Long Acting GnRH Antagonist Degarelix in Women With Endometriosis Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Endocrinology and Reproductive Medicine, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Endocrinology and Reproductive Medicine, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The long acting GnRH antagonist degarelix will be tested for the treatment of women with
      endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom
      disappearance and disease free time during follow-up will be the outcomes for establishing
      which medical treatment is the best in endometriosis recurrence treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing
      recurrence after surgery at least in 20-50% after 5 years of follow-up. The long acting GnRH
      antagonist degarelix, which do not have the flare-up effect at the opposite of GnRH agonist
      and strongly suppress LH secretion and thecal cell activity may show a better effects on
      endometrial implants than GnRH agonist.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free time</measure>
    <time_frame>24 months</time_frame>
    <description>time without pain symptoms due to the disease recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time of disappearance pain</measure>
    <time_frame>24 months</time_frame>
    <description>time needed during treatment to improve the pain symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>reduction of endometriosis lesions</measure>
    <time_frame>24 months</time_frame>
    <description>endometriosis lesions regression during treatment evidenced by MRI scan</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Degarelix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 women will be treated with degarelix 80mg in one administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Goserelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>goserelin 3.6mg monthly for three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>degarelix</intervention_name>
    <description>50 women will be treated with degarlix 80 mg, in only one administration covering three months</description>
    <arm_group_label>Degarelix</arm_group_label>
    <other_name>firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin</intervention_name>
    <description>50 women will be treated with decapeptyl 3.6 every month for three months</description>
    <arm_group_label>Goserelin</arm_group_label>
    <other_name>decapeptyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women affected by endometriosis showing recurrence of pain symptoms

          -  previous surgery for endometriosis

        Exclusion Criteria:

          -  presence of other systemic diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARCO SBRACIA, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cerm-Hungaria</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>October 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <keyword>long acting GnRH antagonist</keyword>
  <keyword>Degarelix</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Pelvic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

